Cognition Therapeutics(CGTX)
$0.64-0.04 (-6.04%)
CGTX
Cognition Therapeutics stock drug pipeline
$0.64
At close:-0.04 (-6.04%)
Want to see CGTX full AI Analyst Report?
Cognition Therapeutics (CGTX) Drug Pipeline
655 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Active Comparator Ct1812 | Age-Related Macular Degeneration | Phase II | Terminated | Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD). | May 17, 2023 | ― |
| Ct1812 | Early Alzheimer's Disease | Phase II | Active Not Recruiting | A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease | Aug 08, 2022 | ― |
| Ct1812 | Dementia With Lewy Bodies | Phase II | Completed | Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies | Jan 11, 2022 | ― |
| Ct1812 | Alzheimer Disease | Phase II | Completed | Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG | Jan 30, 2020 | ― |
| Ct1812 | Mild To Moderate Alzheimer's Disease | Phase II | Completed | A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease. | Apr 10, 2018 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Active Comparator Ct1812 | Phase II | Age-Related Macular Degeneration | Terminated | Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD). | May 17, 2023 | ― |
| Ct1812 | Phase II | Early Alzheimer's Disease | Active Not Recruiting | A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease | Aug 08, 2022 | ― |
| Ct1812 | Phase II | Dementia With Lewy Bodies | Completed | Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies | Jan 11, 2022 | ― |
| Ct1812 | Phase II | Alzheimer Disease | Completed | Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG | Jan 30, 2020 | ― |
| Ct1812 | Phase II | Mild To Moderate Alzheimer's Disease | Completed | A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease. | Apr 10, 2018 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Cognition Therapeutics, Inc. (CGTX) have in its pipeline
Cognition Therapeutics CGTX is currently developing the following drugs: Active Comparator Ct1812, Ct1812. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

